Neopharmed to Acquire Orladeyo's European Operations in $250M Deal
Deal News | Jun 27, 2025 | Legal Community Italy
Neopharmed Gentili, an Italian pharmaceutical company partially owned by the Del Bono family alongside Ardian and Renaissance Partners, has entered into an agreement to acquire the European operations of Orladeyo from BioCryst Pharmaceuticals. The deal is valued at $250 million, with the potential for an additional $14 million based on future sales milestones in Central and Eastern Europe. The acquisition, expected to close by October 2025, will be financed through a combination of Neopharmed's available liquidity and contributions from its shareholders. As part of the agreement, Neopharmed Gentili will also manage European sales royalties. PwC TLS provided tax due diligence and tax structuring services, while PwC handled financial due diligence for Neopharmed Gentili.
Sectors
- Pharmaceuticals
- Private Equity
Geography
- Italy – Neopharmed Gentili is an Italian company, making Italy a key geographic focus of the article.
- United States – BioCryst Pharmaceuticals, the company selling its European operations of Orladeyo, is based in the United States, thus engaging with the US in this transaction.
Industry
- Pharmaceuticals – The core activity of Neopharmed Gentili and BioCryst Pharmaceuticals involves drug development and distribution, placing this deal within the pharmaceuticals industry.
- Private Equity – Involvement of private equity firms Ardian and Renaissance Partners in owning Neopharmed Gentili highlights the private equity sector's influence in this acquisition.
Financials
- $250 million – Initial payment from Neopharmed Gentili to BioCryst for the acquisition.
- $14 million – Potential future milestone payments contingent on sales performance.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Neopharmed Gentili | Buyer | Company | An Italian pharmaceutical company acquiring the European operations of Orladeyo. |
| BioCryst Pharmaceuticals | Vendor | Company | A US-based pharmaceutical company selling its European operations of Orladeyo. |
| Ardian | Co-owner | Company | A private equity firm that partially owns Neopharmed Gentili. |
| Renaissance Partners | Co-owner | Company | A private equity firm that partially owns Neopharmed Gentili. |
| PwC TLS | Legal Advisor | Company | Provided tax due diligence and tax structuring services for Neopharmed Gentili. |
| PwC | Financial Advisor | Company | Handled financial due diligence for Neopharmed Gentili. |
| Nicola Broggi | Partner at PwC TLS | Person | Part of the team providing tax due diligence and structuring for Neopharmed. |